Pricing power: 2 ASX shares that can fight stagflation

The clouds darkening the skies right now look just like the 1970s. Here's a pair of investments that can withstand the pressure.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

No doubt share investors are sick of hearing it by now, but higher costs for everything and rising interests will dominate market fortunes for the foreseeable future.

According to T Rowe Price Group Inc (NASDAQ: TROW) head of Australian equities Randal Jenneke, the current situation bears similarities to the 1970s "stagflation" era.

"Headlines feature daily around the rising cost of fuel, electricity and commodity prices," he said.

"At the same time, a tight labour market sparks worries of a wage-price spiral and broader fears of a hot and embedded inflation that will be difficult to cool."

Thankfully, though, there are some differences. For example, the energy shortage is much more acute in Europe this time, as the US is a net exporter — not an importer as it was back in the 1970s.

"Consumer and corporate balance sheets are also stronger… The lessons from the stagflation period are still very real in the minds of central bankers and they are likely to do whatever possible to ensure we do not repeat history," said Jenneke.

"With this in mind, we view a stagflation replay as only a 15% to 20% chance."

Regardless, investors still need to be careful. 

Jenneke suggested buyers of ASX shares need to move their focus from revenue growth to margin sustainability.

"A repeat of the 70s stagflation era is not our base case. However, the parallels continue to grow."

Two kids in superhero capes.

Image source: Getty Images

Nothing beats setting your own prices

So which businesses can protect their margins in times of rising input costs and cooling consumer sentiment?

"Those that can better manage through this period will likely be companies with strong pricing power," said Jenneke.

"To pass on costs effectively to buyers requires a good industry structure, differentiated products and defensive volumes."

The T Rowe Price team reckons the healthcare industry fulfils many of those criteria.

Jenneke singled out one name in particular.

"Resmed CDI (ASX: RMD), for example, has a large underpenetrated market," he said.

"And despite various input and logistics cost pressures, has been able to pass through price increases given their dominant market share and current lack of reputable competition."

Infrastructure also has the pricing power that Jenneke's analysts are currently seeking.

"Transurban Group (ASX: TCL), for example, has built-in price increases for its contracts. The nature of its cost structure brings high EBIT margins and margin stability," he said.

"Anecdotally, you know the cost of tolls are rising when every second taxi driver makes a point or two about it."

One important note about these ASX shares is that Jenneke very much likes the businesses independent of the economic headwinds.

"Another lesson from the 1970s is that the global macro picture does not trump company fundamentals," he said.

"For example, both the US and UK faced a similar stagflation narrative. However, UK banks performed terribly amid a severe property price crunch, while their US peers outperformed."

Motley Fool contributor Tony Yoo has positions in ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Investing Strategies

A young man talks tech on his phone while looking at a laptop with a financial graph superimposed across the image.
Growth Shares

3 ASX growth shares to buy with $10,000

Looking to add some growth shares to your portfolio? Here are three that brokers rate as buys.

Read more »

Two smiling work colleagues discuss an investment at their office.
Growth Shares

3 ASX 300 shares that could be much bigger in 5 years

Big returns could be on offer from these shares according to analysts.

Read more »

A smiling woman sits in a cafe reading a story on her phone about Rio Tinto and drinking a coffee with a laptop open in front of her.
Investing Strategies

Why I'd buy these ASX 200 stocks if I were a beginner

I think building a beginner portfolio is about choosing businesses you can understand and hold with confidence.

Read more »

Smiling couple sitting on a couch with laptops fist pump each other.
Cheap Shares

Buy and forget? 2 top ASX shares built for the long term

Experts are upbeat and see upside of up to 65%.

Read more »

two young boys dressed in business suits and wearing spectacles look at each other in rapture with wide open mouths and holding large fans of banknotes with other banknotes, coins and a piggybank on the table in front of them and a bag of cash at the side.
Investing Strategies

One ASX share to double, one yielding 11% — ASX picks for April

This mix can help build both wealth and retirement income.

Read more »

Two brokers analysing the share price with the woman pointing at the screen and man talking on a phone.
Growth Shares

3 ASX shares tipped to grow 75% or more in the next 12 month!

These businesses may be significantly undervalued.

Read more »

A woman looks excited as she holds Australian dollars in the air.
Growth Shares

2 undervalued ASX shares to buy that experts think could deliver strong returns

A fund manager thinks these ASX shares could deliver great returns.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Orthocell shares soar 22% on landmark US breakthrough

The company has been given approval to sell Remplir in more than 220 hospitals in the US.

Read more »